AVR.US Anteris Technologies Global Corp. Common Stock
- Market cap
- USD 528M
- P/E
- -
- P/B
- 2.52x
- ROE
- -46.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AVR.US undervalued?
Graham numberThe Graham number of Anteris Technologies Global Corp. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anteris Technologies Global Corp. Common Stock fundamental analysis
No fundamental analysis for Anteris Technologies Global Corp. Common Stock yet.
Anteris Technologies Global Corp. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anteris Technologies Global Corp. Common Stock
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenog…
Full company profileAnteris Technologies Global Corp. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anteris Technologies Global Corp. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 5.46M | 5.83M | 3.20M | 2.73M | 2.70M | 1.91M | 2.70M |
| Gross Profit | 3.36M | 1.91M | 298K | 877K | 1.27M | -317K | 1.49M |
| Operating Income | -13.3M | -16.9M | -31.1M | -48.1M | -78.4M | -93.9M | -113M |
| EBITDA | -13.6M | -15.5M | -29.1M | -45.5M | -74.4M | -92.5M | -103M |
| Net Income | -11.8M | -17.2M | -30.6M | -46.0M | -76.3M | -94.1M | -105M |
| EPS | -0.33 | -0.48 | -0.85 | -1.28 | -3.77 | -2.55 | -1.08 |
| Balance Sheet | |||||||
| Total Assets | 9.75M | 21.4M | 16.0M | 30.5M | 80.7M | 23.0M | 262M |
| Total Liabilities | 7.90M | 10.9M | 6.95M | 11.6M | 18.0M | 23.3M | 35.4M |
| Shareholders' Equity | 1.86M | 10.5M | 9.03M | 19.3M | 62.8M | -93.0K | 227M |
| Cash & Short-term Investments | 3.36M | 15.5M | 9.35M | 21.1M | 70.5M | 12.6M | 233M |
| Total Debt | 2.92M | 4.14M | 953K | 1.69M | 1.40M | 2.28M | 16.1M |
| Cash Flow | |||||||
| Operating Cash Flow | -11.1M | -14.4M | -29.4M | -34.6M | -61.2M | -77.8M | -96.5M |
| Capital Expenditure | 222K | 582K | 1.67M | 2.39M | 2.27M | 1.95M | 2.91M |
| Free Cash Flow | -11.3M | -15.0M | -31.1M | -37.0M | -63.5M | -79.8M | -99.4M |
| Ratios | |||||||
| ROE | -634.5% | -163.1% | -338.3% | -238.4% | -121.6% | - | -46.4% |
| ROA | -120.7% | -80.1% | -191.2% | -150.8% | -94.5% | -409.4% | -40.1% |
| Net Profit Margin | -215.8% | -294.5% | -954.9% | -1,682.8% | -2,822.5% | -4,921.3% | -3,904.7% |
| Debt to Equity | 1.57x | 0.39x | 0.11x | 0.09x | 0.02x | - | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anteris Technologies Global Corp. Common Stock dividends
Anteris Technologies Global Corp. Common Stock has not paid dividends in the last 7 fiscal years.
Who owns Anteris Technologies Global Corp. Common Stock
- Insiders 16.55%
- Institutions 72.61%
- Public & others 10.84%
- Shares outstanding 97.3M
- Free float 68.7M
Top funds holding AVR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Series International Sm Cap | 1.99M | 2.04% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 1.94M | 1.99% | 0.00% | Oct 2026 |
| Fidelity Pacific Basin | 1.80M | 1.84% | 0.00% | Sep 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 1.44M | 1.48% | +16.15% | Jan 2026 |
| Fidelity Advisor Intl Sm Cap Opps I | 1.38M | 1.42% | +1.37% | Aug 2026 |
| Fidelity Small Cap Index | 895K | 0.92% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 717K | 0.74% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 446K | 0.46% | -5.07% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 428K | 0.44% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 379K | 0.39% | +0.17% | Sep 2026 |
| Fidelity Series Small Cap Core | 351K | 0.36% | -5.23% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 319K | 0.33% | -21.47% | Sep 2026 |
| JNL Multi-Manager Intl Sm Cp I | 254K | 0.26% | 0.00% | Sep 2026 |
| Stt Strt® SPDR® S&P®HlthCrEqpmntETF | 251K | 0.26% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 232K | 0.24% | 0.00% | Oct 2026 |
| Fidelity High Income | 218K | 0.22% | 0.00% | Jul 2026 |
| Vanguard US Momentum Factor ETF | 217K | 0.22% | 0.00% | Sep 2026 |
| Fidelity Small Cap Discovery | 210K | 0.22% | 0.00% | Aug 2026 |
| Fidelity SAI High Income | 199K | 0.20% | 0.00% | Jul 2026 |
| JPMorgan Small Cap Value I | 194K | 0.20% | -2.06% | Sep 2026 |
Top institutions holding AVR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| L1 Capital Pty Ltd | 7.79M | 7.99% | 0.00% | Jun 2026 |
| FMR Inc | 6.87M | 7.05% | +136.72% | Jun 2026 |
| Nantahala Capital Management, LLC | 6.77M | 6.94% | +22.34% | Jun 2026 |
| BlackRock Inc | 5.77M | 5.92% | +18.04% | Jun 2026 |
| Sio Capital Management, LLC | 5.55M | 5.69% | +3.03% | Jun 2026 |
| Perceptive Advisors LLC | 3.43M | 3.51% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 3.15M | 3.23% | -17.00% | Jun 2026 |
| Bvf Inc | 3.00M | 3.08% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 3.00M | 3.08% | 0.00% | Jun 2026 |
| Ensign Peak Advisors Inc | 2.39M | 2.45% | +14.52% | Jun 2026 |
| Geode Capital Management, LLC | 2.10M | 2.16% | +14.18% | Jun 2026 |
| State Street Corp | 1.71M | 1.75% | +39.74% | Jun 2026 |
| Rhenman Partners Asset Management AB | 1.54M | 1.58% | +6.95% | Jun 2026 |
| Assenagon Asset Management SA | 1.29M | 1.32% | 0.00% | Jun 2026 |
| Vestal Point Capital LP | 1.01M | 1.04% | -11.77% | Jun 2026 |
| Affinity Asset Advisors, LLC | 912K | 0.94% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 880K | 0.90% | +2.56% | Jun 2026 |
| Suvretta Capital Management, LLC | 850K | 0.87% | 0.00% | Jun 2026 |
| UBS Group AG | 752K | 0.77% | -46.53% | Jun 2026 |
| Velan Capital Investment Management LP | 700K | 0.72% | 0.00% | Jun 2026 |
Anteris Technologies Global Corp. Common Stock company profile
- Company name
- Anteris Technologies Global Corp. Common Stock
- Ticker
- AVR.US
- Exchange
- USA Stocks
- Listed since
- Dec 13, 2024
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 174
- Fiscal year end
- December
- Address
- Toowong Tower, Toowong, QLD, Australia, 4066
- Phone
- 61 7 3152 3200
- Website
- anteristech.com
About Anteris Technologies Global Corp. Common Stock
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Anteris Technologies Global Corp. Common Stock management
6- Mr. Wayne Geoffrey PatersonVice Chairman & CEO · born 1967
- Mr. David St. DenisPresident & Director · born 1969
- Mr. Matthew McDonnellHead of Australia · born 1973
- Mr. Brent A. MoenChief Financial Officer · born 1967
- Mr. Eric Ian Schwartz J.D.Chief Legal Officer · born 1969
- Dr. Chris Meduri M.D., M.P.H.Chief Medical Officer & Member of Medical Advisory Board